Billions Co Ltd

Billions Co Ltd has a liquidity position that is marginally balanced, with a current ratio of 0.9, indicating that its current liabilities slightly exceed its current assets. The company holds KRW 13,283,981,620 in cash and equivalents, but this is offset by KRW 15,135,753,780 in long-term debt, resulting in a net cash position that is negative. This suggests a potential liquidity risk, especially if the company faces unexpected cash outflows or a decline in operating cash flow [doc:044480.KQ]. Profitability metrics for Billions Co Ltd are weak, with a return on equity (ROE) of -29.1% and a return on assets (ROA) of -14.65%. These figures are significantly below the industry median for pharmaceutical companies, which typically exhibit positive ROE and ROA. The company reported a net loss of KRW 7,133,786,860 and an operating loss of KRW 1,931,629,150, indicating that it is not currently generating sufficient revenue to cover its operating costs [doc:044480.KQ]. The company's revenue is derived from multiple segments, including pharmaceuticals, rubber products, and software development. However, the financial data does not provide a breakdown of revenue by segment or geography, making it difficult to assess the concentration of risk in any particular area. Given the lack of detailed segment reporting, it is unclear whether the company is over-reliant on any one product line or geographic market [doc:044480.KQ]. Looking ahead, the company's growth trajectory appears uncertain. The financial snapshot does not provide forward-looking revenue guidance, but the recent operating and net losses suggest that the company may face challenges in achieving revenue growth in the near term. The capital expenditure of KRW 382,910,010 indicates some level of investment in the business, but the negative free cash flow of KRW 6,416,300,730 suggests that the company is not generating enough cash to fund its operations and investments without external financing [doc:044480.KQ]. The risk assessment for Billions Co Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to respond to financial stress. However, the low dilution risk suggests that the company is not currently issuing a large number of new shares, which could help preserve shareholder value [doc:044480.KQ]. Recent events and disclosures indicate that the company is operating in a challenging environment. The most recent earnings report shows a significant loss, and the company's operating cash flow is relatively low compared to its debt obligations. There are no recent filings or transcripts provided that detail specific strategic initiatives or operational changes, but the company's diverse product portfolio may offer some resilience in the face of market volatility [doc:044480.KQ].